Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803 Journal Article


Authors: Ng, K.; Ogino, S.; Meyerhardt, J. A.; Chan, J. A.; Chan, A. T.; Niedzwiecki, D.; Hollis, D.; Saltz, L. B.; Mayer, R. J.; Benson, A. B. 3rd; Schaefer, P. L.; Whittom, R.; Hantel, A.; Goldberg, R. M.; Bertagnolli, M. M.; Venook, A. P.; Fuchs, C. S.
Article Title: Relationship between statin use and colon cancer recurrence and survival: Results from CALGB 89803
Abstract: Background Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. Methods We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan-Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Results Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis (P(trend) = .63, .63, and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups (P(interaction) = .84, .67, and .98 for DFS, RFS, and OS, respectively). Conclusion Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status. J Natl Cancer Inst 2011; 103: 1540-1551
Keywords: risk; follow-up; colorectal-cancer; phase-ii; growth-factor; disease; prevention; transferase inhibitor r115777; kras mutation detection; cholesterol levels
Journal Title: JNCI: Journal of the National Cancer Institute
Volume: 103
Issue: 20
ISSN: 0027-8874
Publisher: Oxford University Press  
Date Published: 2011-10-19
Start Page: 1540
End Page: 1551
Language: English
ACCESSION: WOS:000296107700011
DOI: 10.1093/jnci/djr307
PROVIDER: wos
PMCID: PMC3196479
PUBMED: 21849660
Notes: --- - Article - "Source: Wos"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Leonard B Saltz
    791 Saltz